# Menopause Hormone Therapy Lost Its Black Box. The Harder Conversation Starts Now > In November 2025, regulators removed most of the boxed warning that had defined hormone therapy since 2002. The science behind the shift is about timing, and the remaining risks are still worth a real conversation. - Publication: New England Anti-Aging (https://newenglandantiaging.com) - Department: The Long Read - Label: Analysis - Section: Hormones - Author: Jess Albrecht, Staff Writer, Hormones - Published: 2026-11-10 - Lead photograph: Two women walking up a grassy hill path, by Jim Luo on Unsplash (https://unsplash.com/photos/two-women-walk-up-a-grassy-hill-path-pUPJxe_KmrE) - Canonical URL: https://newenglandantiaging.com/hormones/menopause-hormone-therapy-one-year-later/ ## The Short Version - The FDA removed boxed warning language on heart disease, breast cancer and dementia from menopausal hormone therapy in November 2025. - The warning about endometrial cancer stays for estrogen-only products used by women who still have a uterus. - Benefits look most favorable for women who start before 60 or within 10 years of their final period. For more than two decades, every woman who picked up an estrogen prescription in the United States also picked up a black box. The boxed warning, the most serious caution the Food and Drug Administration can place on a drug label, listed heart disease, stroke, breast cancer and probable dementia. Many women read it and never filled the prescription. Many doctors stopped offering it. In November 2025, that changed. The [FDA announced](https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy-0) that it was removing the boxed warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products. One boxed warning remains. Estrogen-only therapy in women who still have a uterus raises the risk of endometrial cancer, which is why those women are prescribed a progestogen alongside it. A year on, the question in exam rooms is less about whether hormone therapy is allowed and more about whether it is right for a particular woman. ## How we got here The warning traces back to July 2002, when the Women's Health Initiative stopped its estrogen plus progestin trial early. The [results in JAMA](https://doi.org/10.1001/jama.288.3.321) reported more breast cancers, heart attacks, strokes and blood clots in women taking combined hormones than in women taking placebo. The news landed as a shock. Prescriptions fell sharply within months. What got less attention was who the trial enrolled. The average participant was 63 years old, more than a decade past menopause for most. The study was designed to test whether hormones prevented chronic disease in older women, not whether they were safe for a 51-year-old with night sweats. Over the years that followed, researchers kept reanalyzing the data by age. A [2017 follow-up in JAMA](https://doi.org/10.1001/jama.2017.11217) looked at about 18 years of mortality data from both WHI hormone trials. Hormone therapy for five to seven years was not associated with an increase in all-cause, cardiovascular or cancer death over the long run. Among the youngest women, the trend pointed toward benefit, though not decisively. > The trial was designed to test whether hormones prevented disease in older women, not whether they were safe for a 51-year-old with night sweats. ## The timing idea The concept that ties the evidence together is often called the timing hypothesis. Estrogen appears to act differently on blood vessels that are still relatively healthy than on vessels that already have significant plaque. Starting hormone therapy near menopause may carry a very different risk profile than starting it at 65. That is reflected in the [2022 position statement](https://doi.org/10.1097/GME.0000000000002028) from The North American Menopause Society, now called The Menopause Society. For healthy women younger than 60 or within 10 years of menopause onset, the society concluded that the benefits of hormone therapy generally outweigh the risks for treating bothersome hot flashes and for preventing bone loss in women at elevated risk. The balance becomes less favorable for women who start later. ## Risks that have not gone away Removing a warning box does not remove risk. It changes how risk is communicated. Women and their clinicians should still weigh several things. Breast cancer risk with combined estrogen plus progestogen appears to rise with longer duration of use. Estrogen alone, in women without a uterus, has looked more neutral and in some analyses favorable. Oral estrogen raises the risk of blood clots more than transdermal patches or gels do, which matters for women with a history of clots or other clotting risk. A personal history of breast cancer, unexplained vaginal bleeding, active liver disease or prior stroke generally rules systemic therapy out or calls for specialist input. Some experts criticized the speed and process of the 2025 decision, arguing it relied more on expert opinion than on new trial data. That debate is worth knowing about. It is also not a reason to return to blanket avoidance, which left millions of women suffering through symptoms that are very treatable. ## What a good visit looks like A thoughtful hormone therapy consultation is personal. It starts with symptoms and goals, which might be hot flashes, sleep disruption, vaginal dryness, mood changes or bone health. It covers family history, blood pressure, clotting risk and breast screening. It considers the route, since a patch and a pill are not interchangeable, and the dose, which is usually the lowest that works. Local vaginal estrogen for genitourinary symptoms is its own category. It delivers very little hormone to the rest of the body and has a much simpler risk profile. Perimenopause can begin in a woman's early forties, years before periods stop, and its first signs are often irregular cycles, poor sleep or mood changes rather than hot flashes. Women in that window often wait for symptoms to become unbearable before raising them. With the timing rules in the current evidence, an earlier conversation keeps more options open. Bring a few weeks of notes on sleep, cycles and symptoms. It makes the appointment far more productive than a general description. ## What the Evidence Doesn't Settle The 2025 decision drew criticism. The National Center for Health Research argued the FDA skipped its usual advisory committee process and relied on a panel of invited experts who largely favored hormone therapy, and some researchers note that breast cancer risk with combined estrogen and progestogen is real and rises with duration. Supporters counter that a single boxed warning overstated risk for younger, healthy women and kept many from effective treatment. ## Notes and Sources 1. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. U.S. Food and Drug Administration, 2025. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy-0 2. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women, Principal Results From the Women's Health Initiative. JAMA, 2002. https://doi.org/10.1001/jama.288.3.321 3. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA, 2017. https://doi.org/10.1001/jama.2017.11217 4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 2022. https://doi.org/10.1097/GME.0000000000002028 --- Published by New England Anti-Aging, the health and longevity magazine of Align Wellness, 250 Centerville Rd, Building E, Warwick, RI 02886. General information only, not medical advice.